Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Detecting the disappearance of RAS-mutant clones in the plasma of patients with RAS-mutant mCRC to select patient candidates for anti-EGFR treatment and to monitor resistance to treatment.

Raimondi C, Loreni F, Nicolazzo C, Belardinilli F, Wilson A, Gradilone A, Giannini G, Gazzaniga P, Cortesi E.

Ann Oncol. 2019 Jul;30 Suppl 4:iv38. doi: 10.1093/annonc/mdz155.140. Epub 2019 Dec 4. No abstract available.

PMID:
32085139
2.

Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer.

Nicolazzo C, Belardinilli F, Caponnetto S, Gradilone A, Cortesi E, Giannini G, Gazzaniga P.

Front Oncol. 2019 Dec 17;9:1414. doi: 10.3389/fonc.2019.01414. eCollection 2019. No abstract available.

3.

Identification of novel BRCA1 large genomic rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data.

Nicolussi A, Belardinilli F, Silvestri V, Mahdavian Y, Valentini V, D'Inzeo S, Petroni M, Zani M, Ferraro S, Di Giulio S, Fabretti F, Fratini B, Gradilone A, Ottini L, Giannini G, Coppa A, Capalbo C.

PeerJ. 2019 Nov 15;7:e7972. doi: 10.7717/peerj.7972. eCollection 2019.

4.

EpCAMlow Circulating Tumor Cells: Gold in the Waste.

Nicolazzo C, Gradilone A, Loreni F, Raimondi C, Gazzaniga P.

Dis Markers. 2019 Sep 17;2019:1718920. doi: 10.1155/2019/1718920. eCollection 2019. Review.

5.

Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer.

Nicolazzo C, Raimondi C, Gradilone A, Emiliani A, Zeuner A, Francescangeli F, Belardinilli F, Seminara P, Loreni F, Magri V, Tomao S, Gazzaniga P.

Cancers (Basel). 2019 Jul 24;11(8). pii: E1042. doi: 10.3390/cancers11081042.

6.

Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial.

Nicolazzo C, Busetto GM, Gradilone A, Sperduti I, Del Giudice F, Loreni F, Cortesi E, de Berardinis E, Gazzaniga P, Raimondi C.

Oncologist. 2019 May;24(5):612-616. doi: 10.1634/theoncologist.2018-0784. Epub 2019 Apr 3.

7.

Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test.

Nicolazzo C, Gradilone A, Gazzaniga P.

JAMA Oncol. 2019 Mar 1;5(3):433-434. doi: 10.1001/jamaoncol.2018.6683. No abstract available.

PMID:
30703189
8.

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer.

Raimondi C, Nicolazzo C, Belardinilli F, Loreni F, Gradilone A, Mahdavian Y, Gelibter A, Giannini G, Cortesi E, Gazzaniga P.

Cancers (Basel). 2019 Jan 4;11(1). pii: E42. doi: 10.3390/cancers11010042.

9.

Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion.

Nicolazzo C, Gradilone A, Carpino G, Gazzaniga P, Raimondi C.

Methods Mol Biol. 2019;1884:247-258. doi: 10.1007/978-1-4939-8885-3_17.

PMID:
30465208
10.

Coexistence of three EGFR mutations in an NSCLC patient: A brief report.

Belardinilli F, Gradilone A, Gelibter A, Zani M, Occhipinti M, Ferraro S, Nicolazzo C, Coppa A, Giannini G.

Int J Biol Markers. 2018 Jun 1:1724600818782200. doi: 10.1177/1724600818782200. [Epub ahead of print]

PMID:
29945477
11.

Liquid Biopsy in Rare Cancers: Lessons from Hemangiopericytoma.

Nicolazzo C, Colangelo L, Corsi A, Carpino G, Gradilone A, Sonato C, Raimondi C, Gaudio E, Gazzaniga P, Gianni W.

Anal Cell Pathol (Amst). 2018 Mar 7;2018:9718585. doi: 10.1155/2018/9718585. eCollection 2018.

12.

PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system?

Raimondi C, Carpino G, Nicolazzo C, Gradilone A, Gianni W, Gelibter A, Gaudio E, Cortesi E, Gazzaniga P.

Oncoimmunology. 2017 Apr 20;6(12):e1315488. doi: 10.1080/2162402X.2017.1315488. eCollection 2017.

13.
14.

EpCAM-expressing circulating tumor cells in colorectal cancer.

Nicolazzo C, Raimondi C, Francescangeli F, Ceccarelli S, Trenta P, Magri V, Marchese C, Zeuner A, Gradilone A, Gazzaniga P.

Int J Biol Markers. 2017 Oct 31;32(4):e415-e420. doi: 10.5301/ijbm.5000284.

PMID:
28604994
15.

The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC).

Nicolazzo C, Busetto GM, Del Giudice F, Sperduti I, Giannarelli D, Gradilone A, Gazzaniga P, de Berardinis E, Raimondi C.

J Cancer Res Clin Oncol. 2017 Oct;143(10):1971-1976. doi: 10.1007/s00432-017-2449-8. Epub 2017 May 29.

PMID:
28555356
16.

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.

Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O, Mastromartino M, Del Bene G, Prete A, Longo F, Cortesi E, Gazzaniga P.

Sci Rep. 2016 Aug 24;6:31726. doi: 10.1038/srep31726.

17.

Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method.

Bozzetti C, Quaini F, Squadrilli A, Tiseo M, Frati C, Lagrasta C, Azzoni C, Bottarelli L, Galetti M, Alama A, Belletti S, Gatti R, Passaro A, Gradilone A, Cavazzoni A, Alfieri R, Petronini PG, Bonelli M, Falco A, Carubbi C, Pedrazzi G, Nizzoli R, Naldi N, Pinto C, Ardizzoni A.

PLoS One. 2015 Nov 16;10(11):e0142891. doi: 10.1371/journal.pone.0142891. eCollection 2015.

18.

Impact of chronic exposure to bevacizumab on EpCAM-based detection of circulating tumor cells.

Nicolazzo C, Massimi I, Lotti LV, Vespa S, Raimondi C, Pulcinelli FM, Gradilone A, Gazzaniga P.

Chin J Cancer Res. 2015 Oct;27(5):491-6. doi: 10.3978/j.issn.1000-9604.2015.04.09.

19.

Circulating tumor cells isolation: the "post-EpCAM era".

Raimondi C, Nicolazzo C, Gradilone A.

Chin J Cancer Res. 2015 Oct;27(5):461-70. doi: 10.3978/j.issn.1000-9604.2015.06.02. Review.

20.

Significance of circulating tumor cells in soft tissue sarcoma.

Nicolazzo C, Gradilone A.

Anal Cell Pathol (Amst). 2015;2015:697395. doi: 10.1155/2015/697395. Epub 2015 Jun 18. Review.

21.

The rationale for liquid biopsy in colorectal cancer: a focus on circulating tumor cells.

Gazzaniga P, Raimondi C, Nicolazzo C, Carletti R, di Gioia C, Gradilone A, Cortesi E.

Expert Rev Mol Diagn. 2015;15(7):925-32. doi: 10.1586/14737159.2015.1045491. Epub 2015 May 9. Review.

PMID:
25959553
22.

Clinical utility of circulating tumor cell counting through CellSearch(®): the dilemma of a concept suspended in Limbo.

Raimondi C, Gradilone A, Naso G, Cortesi E, Gazzaniga P.

Onco Targets Ther. 2014 Apr 17;7:619-25. doi: 10.2147/OTT.S46200. eCollection 2014. Review.

23.

Circulating tumor cells in early bladder cancer: insight into micrometastatic disease.

Raimondi C, Gradilone A, Gazzaniga P.

Expert Rev Mol Diagn. 2014 May;14(4):407-9. doi: 10.1586/14737159.2014.908119. Epub 2014 Apr 10.

PMID:
24717055
24.

Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer.

Gazzaniga P, de Berardinis E, Raimondi C, Gradilone A, Busetto GM, De Falco E, Nicolazzo C, Giovannone R, Gentile V, Cortesi E, Pantel K.

Int J Cancer. 2014 Oct 15;135(8):1978-82. doi: 10.1002/ijc.28830. Epub 2014 Mar 13.

25.

Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer.

Raimondi C, Nicolazzo C, Gradilone A, Giannini G, De Falco E, Chimenti I, Varriale E, Hauch S, Plappert L, Cortesi E, Gazzaniga P.

Cancer Biol Ther. 2014 May;15(5):496-503. doi: 10.4161/cbt.28020. Epub 2014 Feb 12.

26.

Controversies in circulating tumor cell count during therapy.

Raimondi C, Gradilone A, Gazzaniga P.

Expert Rev Mol Diagn. 2013 Jun;13(5):499-507. doi: 10.1586/erm.13.33. Review.

PMID:
23782256
27.

Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?

Gazzaniga P, Raimondi C, Gradilone A, Biondi Zoccai G, Nicolazzo C, Gandini O, Longo F, Tomao S, Lo Russo G, Seminara P, Vincenzi B, Chimenti I, Cristofanilli M, Frati L, Cortesi E.

J Cancer Res Clin Oncol. 2013 Aug;139(8):1411-6. doi: 10.1007/s00432-013-1450-0. Epub 2013 Jun 5.

PMID:
23736274
28.

Circulating tumor cells in high-risk nonmetastatic colorectal cancer.

Gazzaniga P, Gianni W, Raimondi C, Gradilone A, Lo Russo G, Longo F, Gandini O, Tomao S, Frati L.

Tumour Biol. 2013 Oct;34(5):2507-9. doi: 10.1007/s13277-013-0752-9. Epub 2013 Mar 29.

PMID:
23539436
29.

Prognostic significance of tyrosinase expression in sentinel lymph node biopsy for ultra-thin, thin, and thick melanomas.

Gradilone A, Gazzaniga P, Ribuffo D, Bottoni U, Frati L, Aglian AM, Sorvillo V, Piperno A, Scuderi N, Cigna E.

Eur Rev Med Pharmacol Sci. 2012 Oct;16(10):1367-76.

30.

Circulating tumor cells in young and elderly patients with colorectal cancer: "lupus et agnus".

Gazzaniga P, Gianni W, Gradilone A, Raimondi C, Cortesi E, Frati L.

Aging Clin Exp Res. 2012 Dec;24(6):722-3. doi: 10.3275/8519. Epub 2012 Jul 24. No abstract available.

PMID:
22828412
31.

Morbidity of selective lymph node biopsy for melanoma: meta-analysis of complications.

Cigna E, Gradilone A, Ribuffo D, Gazzaniga P, Fino P, Sorvillo V, Scuderi N.

Tumori. 2012 Jan-Feb;98(1):94-8. doi: 10.1700/1053.11506.

PMID:
22495708
32.

Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis.

Gazzaniga P, Gradilone A, de Berardinis E, Busetto GM, Raimondi C, Gandini O, Nicolazzo C, Petracca A, Vincenzi B, Farcomeni A, Gentile V, Cortesi E, Frati L.

Ann Oncol. 2012 Sep;23(9):2352-6. doi: 10.1093/annonc/mdr619. Epub 2012 Feb 20.

33.

Circulating tumor cells: highlight on practical implications.

Gazzaniga P, Raimondi C, Gradilone A, Naso G, Cortesi E, Frati L.

Mol Diagn Ther. 2012 Feb 1;16(1):7-11. doi: 10.2165/11594520-000000000-00000.

PMID:
22303967
34.

Circulating tumor cells and "suspicious objects" evaluated through CellSearch® in metastatic renal cell carcinoma.

Gradilone A, Iacovelli R, Cortesi E, Raimondi C, Gianni W, Nicolazzo C, Petracca A, Palazzo A, Longo F, Frati L, Gazzaniga P.

Anticancer Res. 2011 Dec;31(12):4219-21.

PMID:
22199284
35.

How circulating tumor cells escape from multidrug resistance: translating molecular mechanisms in metastatic breast cancer treatment.

Gradilone A, Raimondi C, Naso G, Silvestri I, Repetto L, Palazzo A, Gianni W, Frati L, Cortesi E, Gazzaniga P.

Am J Clin Oncol. 2011 Dec;34(6):625-7. doi: 10.1097/COC.0b013e3181f94596.

PMID:
22101388
36.

Circulating tumor cells count and characterization in a male breast cancer patient.

Gazzaniga P, Naso G, Raimondi C, Gradilone A, Palazzo A, Gandini O, Petracca A, Nicolazzo C, Cortesi E, Frati L.

Cancer Biol Ther. 2011 Sep 1;12(5):379-82. Epub 2011 Sep 1.

PMID:
21725206
37.

ABCB5 in peripheral blood of a patient affected by multiple primary malignancies.

Cigna E, Gradilone A, Sorvillo V, Scuderi N.

Ann Ital Chir. 2011 Jan-Feb;82(1):49-53.

PMID:
21657155
38.

Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero.

Gazzaniga P, Raimondi C, Gradilone A, Di Seri M, Longo F, Cortesi E, Frati L.

Ann Oncol. 2011 Aug;22(8):1929-30. doi: 10.1093/annonc/mdr292. Epub 2011 Jun 1. No abstract available.

39.

Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal.

Gradilone A, Raimondi C, Nicolazzo C, Petracca A, Gandini O, Vincenzi B, Naso G, Aglianò AM, Cortesi E, Gazzaniga P.

J Cell Mol Med. 2011 May;15(5):1066-70. doi: 10.1111/j.1582-4934.2011.01285.x.

40.

Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.

Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F, Cortesi E, Gazzaniga P.

Breast Cancer Res Treat. 2011 Nov;130(2):449-55. doi: 10.1007/s10549-011-1373-x. Epub 2011 Feb 5.

PMID:
21298334
41.

Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization.

Gradilone A, Naso G, Raimondi C, Cortesi E, Gandini O, Vincenzi B, Saltarelli R, Chiapparino E, Spremberg F, Cristofanilli M, Frati L, Aglianò AM, Gazzaniga P.

Ann Oncol. 2011 Jan;22(1):86-92. doi: 10.1093/annonc/mdq323. Epub 2010 Jul 5.

42.

Molecular markers in circulating tumour cells from metastatic colorectal cancer patients.

Gazzaniga P, Gradilone A, Petracca A, Nicolazzo C, Raimondi C, Iacovelli R, Naso G, Cortesi E.

J Cell Mol Med. 2010 Aug;14(8):2073-7. doi: 10.1111/j.1582-4934.2010.01117.x.

43.

CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients.

Gazzaniga P, Cigna E, Panasiti V, Devirgiliis V, Bottoni U, Vincenzi B, Nicolazzo C, Petracca A, Gradilone A.

Eur J Surg Oncol. 2010 Dec;36(12):1211-4. doi: 10.1016/j.ejso.2010.05.001. Epub 2010 Jun 23. No abstract available.

PMID:
20573479
44.

Comment on: isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties.

Gradilone A, Gazzaniga P, Raimondi C, Aglianò AM, Frati L.

Int J Cancer. 2011 Apr 15;128(8):1997-8. doi: 10.1002/ijc.25520. No abstract available.

45.

Tyrosinase expression as a molecular marker for investigating the presence of circulating tumor cells in melanoma patients.

Gradilone A, Cigna E, Aglianò AM, Frati L.

Curr Cancer Drug Targets. 2010 Aug;10(5):529-38. Review.

PMID:
20384579
46.

Circulating tumor cells in cancer therapy: are we off target?

Raimondi C, Naso G, Gradilone A, Gianni W, Cortesi E, Gazzaniga P.

Curr Cancer Drug Targets. 2010 Aug;10(5):509-18. Review.

PMID:
20384574
47.

Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer.

Gradilone A, Petracca A, Nicolazzo C, Gianni W, Cortesi E, Naso G, Vincenzi B, Cristini C, De Berardinis E, Di Silverio F, Aglianò AM, Gazzaniga P.

BJU Int. 2010 Sep;106(5):710-5. doi: 10.1111/j.1464-410X.2009.09130.x.

48.

Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors.

Gazzaniga P, Naso G, Gradilone A, Cortesi E, Gandini O, Gianni W, Fabbri MA, Vincenzi B, di Silverio F, Frati L, Aglianò AM, Cristofanilli M.

Int J Cancer. 2010 May 15;126(10):2437-47. doi: 10.1002/ijc.24953.

49.

A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer.

Gazzaniga P, Gradilone A, de Berardinis E, Sciarra A, Cristini C, Naso G, di Silverio F, Frati L, Aglianò AM.

BJU Int. 2009 Jul;104(2):184-8. doi: 10.1111/j.1464-410X.2008.08342.x. Epub 2009 Jan 19.

50.

Tenascin C: a defensive role in sentinel lymph nodes of melanoma patients?

Gazzaniga P, Cigna E, Vincenzi B, Bottoni U, Vasaturo F, Alfano C, Calvieri S, Frati L, Scuderi N, Aglianò AM, Gradilone A.

J Dermatol Sci. 2009 Mar;53(3):239-41. doi: 10.1016/j.jdermsci.2008.10.005. Epub 2008 Dec 12. No abstract available.

PMID:
19070467

Supplemental Content

Loading ...
Support Center